50591-22-5

Usage

Uses

Used in Pharmaceutical Industry:
1H-Benzimidazol-5-ol,1-methyl-(9CI) is used as a reactant for the preparation of substituted azaquinazolinones. These azaquinazolinones act as modulators of the growth hormone secretagogue receptor 1a (GHSr-1a), which play a crucial role in the treatment of type II diabetes and obesity. By modulating the activity of GHSr-1a, these compounds can help regulate glucose metabolism and improve insulin sensitivity, offering potential therapeutic benefits for patients with these conditions.

Upstream product

• 61679-18-3 4-Methoxy-2-nitro-N-methylaniline 
• 96-96-8 4-methoxy-2-nitroaniline 
• 10394-39-5 5-methoxy-1-methyl-1H-benzo[d]imidazole 
• 4887-80-3 5-methoxy-1H-benzimidazole 
• 616-86-4 2-nitro-4-ethoxyaniline 
• 97953-31-6 toluene-4-sulfonic acid-(4-ethoxy-N-methyl-2-nitro-anilide) 
• 97302-32-4 N-(4-ethoxy-2-nitrophenyl)-4-methylbenzenesulfonamide 
• 3360-78-9 4-methoxy-N-methyl-1,2-phenylenediamine 
• 3360-79-0 N-methyl-4-methoxy-2-nitroaniline 

Downstream Products

• 76971-09-0 1-methyl-4-nitroso-5-benzimidazolol 
• 1228944-43-1 methyl 4-bromo-2-(1-methyl-1H-benzo[d]imidazol-5-yloxy)benzoate 
• 937263-74-6 3-methyl-4-(1-methyl-1H-benzo[d]imidazol-5-yloxy)benzenamine 

Relevant academic research and scientific papers

ERBB RECEPTOR INHIBITORS

Disclosed are compounds inhibiting ErbBs (e. g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.